Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL31411380 | 0.89 | HTR7 (0.46) | TAAR1HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL31411439 | 0.87 | HTR2A (0.48) | HTR2AHTR2CARSLC6A4MPO | |
| SCHEMBL31411344 | 0.80 | MPO (0.39) | TAAR1HTR2AHTR2CHTR2BAR | |
| SCHEMBL13122355 | 0.79 | AR (0.43) | ARSLC6A4MPOGPR84 | |
| Fumaric Acid SCHEMBL31411475 | 0.78 | HTR2A (0.41) | HTR2AHTR2CHTR2BHTR6HTR1A | |
| SCHEMBL5638323 | 0.77 | AR (0.39) | ARSLC6A4MPOGPR84 | |
| SCHEMBL31411355 | 0.76 | HTR2A (0.55) | TAAR1HTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL30998058 | 0.76 | AR (0.38) | ARSLC6A4MPOGPR84 | |
| SCHEMBL8205528 | 0.75 | AR (0.40) | ARSLC6A4MPOGPR84 | |
| SCHEMBL19710704 | 0.74 | HTR2A (0.50) | TAAR1HTR2AHTR2CHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | TAAR1 435/4885HTR2A 94/4885HTR2C 23/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | TAAR1 435/4885HTR2A 94/4885HTR2C 23/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | TAAR1 435/4885HTR2A 94/4885HTR2C 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.